tldrdaily.news logo

KEYTRUDA and Padcev Boost Survival and Response in Cisplatin-Eligible MIBC Patients

1 min read
Source: Merck.com
KEYTRUDA and Padcev Boost Survival and Response in Cisplatin-Eligible MIBC Patients
Photo: Merck.com
TL;DR Summary

Merck announced positive results from the Phase 3 KEYNOTE-B15 trial showing that combining KEYTRUDA (pembrolizumab) with Padcev (enfortumab vedotin) before and after surgery significantly improves survival and response rates in cisplatin-eligible muscle-invasive bladder cancer patients, with a safety profile consistent with known effects.

Topics:business#bladder-cancer#clinical-trial#healthcare#immunotherapy#keytruda#padcev
Share this article
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery  Merck.comView Full Coverage on Google News

Reading Insights

Total Reads

0

Unique Readers

3

Time Saved

48 min

vs 49 min read

Condensed

100%

9,731 → 43 words

Want the full story? Read the original article

Read on Merck.com